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Abstract
Introduction: People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis
use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders
(AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates,
and impact of cannabis use on those with SMI receiving treatment for substance use disorders, a group at
high risk for the negative effects of cannabis use.
Methods: In this secondary data analysis, cannabis use prevalence, correlates, and impact on treatment out-
comes were examined in 121 adults with cooccurring SMI and AUDs receiving outpatient addiction treatment
in a randomized trial of contingency management (CM) for alcohol. Prevalence and frequency of cannabis use
were calculated across the 7-month study period using self-report and urine tests. Cannabis users were com-
pared with nonusers by SMI diagnosis, psychiatric symptoms, medical problems, legal problems, and HIV-risk be-
havior. The relationship between cannabis use and longest duration of alcohol abstinence in participants
randomized to CM (n = 40) was assessed.
Results: Fifty-seven (47%) of participants submitted at least one cannabis-positive urine sample during the study.
Out of the 2834 total samples submitted, 751 (27%) were positive for cannabis. Cannabis users were 2.2 times
more likely to submit an alcohol-positive sample, and 2.5 times more likely to submit a cocaine-positive sample
at baseline, relative to noncannabis users ( p = 0.01). Cannabis users were more likely to engage in risky sexual
behavior ( p = 0.01) and to report being homeless ( p = 0.03) than nonusers. When controlling for pretreatment
alcohol use, the relationship between comorbid cannabis use and alcohol abstinence during CM was not signif-
icant ( p = 0.77).
Conclusion: Rates of comorbid cannabis use were high in this sample of adults with SMI and AUDs. Cannabis use
was correlated with recent alcohol and cocaine use, risky sexual behavior, and homelessness, but not with alco-
hol abstinence during CM.
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Alcohol and cannabis are among the most commonly
used substances worldwide.1 Within the United States,
136 million adults reported alcohol use and 20.5 million
reported cannabis use in the past 30 days.2 Cannabis use
and alcohol use disorders (AUDs) are highly comorbid.
Cannabis users are 32% more likely than nonusers to
have persistent AUDs.3 In the National Epidemiologic
Survey on Alcohol and Related Conditions, 40% of
adults with AUDs reported cannabis use in the past
12 months.4 Co-occurring cannabis and alcohol use is
associated with increased aggressive behavior, interac-
tions with the criminal justice system, and physical
health problems.5 Studies investigating the impact of
comorbid cannabis use on the treatment of alcohol
and other drugs have been inconclusive.6–8
Adults with serious mental illness (SMI), defined as
recurring major depressive, bipolar, and schizophrenia
spectrum disorders, have a lifetime prevalence of canna-
bis use twice as high as that of the general population.9–11
Unfortunately, nearly 50% of adults with SMI will be di-
agnosed with an AUD during their lifetime.12 Adults
with SMI and AUDs may be at a greater risk of negative
consequences of co-occurring cannabis and alcohol use.
Cannabis use is associated withmore persistent psychotic
symptoms, such as increased hallucinations, and alcohol
use is associated with increased risk of HIV infection,
homelessness, incarceration, and intentional and unin-
tentional self-harm.1,9,13,14
Less is known about the prevalence and impact of
comorbid cannabis and alcohol use in adults with SMI.
One study of youth at high risk for psychosis found
that although cannabis use disorders were associated
with increased risk of developing psychosis, alcohol use
moderated this relationship, suggesting that assessing
comorbid alcohol and cannabis use may be important
when understanding the relationship between substance
use and the onset of psychosis.15 Given the high preva-
lence of cannabis and alcohol use in adults with SMI,
as well as previous inconclusive findings regarding the
impact of comorbid cannabis use on alcohol and other
drug treatment outcomes among populations without
SMI, research is needed to better understand the fre-
quency, severity, correlates, and impact of cannabis use
on outcomes in adults with SMI.
Understanding the prevalence, correlates, and relation-
ship of cannabis use with alcohol use and illicit substances
in individuals with SMI is of increasing importance. As of
April 2017, 29 states and the District of Columbia have
legalized medical use of cannabis. Therefore, the objec-
tives of this study were to determine the prevalence and
frequency of cannabis use, demographic and clinical cor-
relates of cannabis use, and the relationship between can-




Participants were recruited between 2012 and 2015
from community health clinics in King County, Wash-
ington, that provide both mental health and addiction
treatment. It should be noted that Washington State’s
Initiative 502 decriminalizing recreational cannabis
use was passed in December 2012 and the first recrea-
tional cannabis was sold in the state on July 8, 2014.
Participants
Participants were recruited as part of a larger study of the
impact of contingency management (CM) on adults with
SMI andAUDs. Participantsmet criteria for (1)Diagnostic
and Statistical Manual of Mental Disorders, fourth edition
(text revision) (DSM-IV-TR) diagnoses of alcohol depen-
dence, (2) recurring major depressive disorder, bipolar
disorder I or II, schizophrenia, or schizoaffective disorder,
as assessed by the Mini-International Neuropsychiatric
Interview (MINI),16 and (3) alcohol use in at least 5 out
of 30 days before baseline. Participants were 18–65
years of age and enrolled in treatment as usual for alco-
hol dependence. Exclusion criteria included significant
risk of dangerous alcohol withdrawal, DSM-IV-TR diag-
nosis of current (within the past year) drug dependence
that suggested physiological dependence (i.e., with-
drawal and tolerance), any medical or psychiatric con-
ditions that could compromise safe study participation,
or inability to provide informed consent. The Univer-
sity of Washington’s Institutional Review Board ap-
proved study procedures.
Measures
Demographic information was collected at the baseline
interview. Participants completed the MINI to assess
for alcohol, drug, mood, and psychotic disorders. At
baseline and weeks 4, 8, 12, 16, 20, 24, and 28, the Addic-
tion Severity Index-Lite was used to assess for days of al-
cohol use, drinking to intoxication, and cannabis and
other drug use in the previous 30 days.17 Psychiatric
symptom severity was assessed using the Positive and
Negative Syndrome Scale (PANSS), a clinician-ratedmea-
sure of schizophrenia-spectrum symptoms, and the Brief
Symptom Inventory (BSI), a self-report measure of
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general psychopathology. TheHIV Risk Taking Behavior
Scale (HRBS) was used to assess risky sexual behavior
and HIV risk.18–20 Participants received gift cards to a
local grocery store for baseline and follow-up interviews.
Participants submitted urine samples for alcohol
and drug testing three times a week during the 4-
week prerandomization phase and the 12-week treatment
period. The primary alcohol use outcome was Diagnostic
Reagents Incorporated ethyl glucuronide enzyme immu-
noassay (EtG-I) conducted onsite using a Thermo Fisher
Indiko analyzer (Fremont, CA). Tests were conducted
using EtG 100ng/mL, 500ng/mL, 1000ng/mL, 2000ng/
mL, and Negative calibrators and EtG 100ng/mL and
375ng/mL controls. Calibrations occurred weekly and
samples were analyzed on the day of collection. Pretreat-
ment EtG levels were calculated for each participant that
ranged from 0 to 2000ng/mL. Pretreatment heavy drink-
ing was defined as an average pretreatment EtG level of
>499ng/mL, a cutoff equivalent to regular heavy drink-
ing, comparedwith <500ng/mL (light drinking).21 During
the treatment phase, samples were considered alcohol neg-
ative if EtG <150ng/mL. Longest duration of alcohol ab-
stinence (LDA) was defined as the highest consecutive
number of EtG-negative urine tests (range 0–36 visits)
during treatment. Point-of-care urine drug tests (Inte-
grated E-Z Split Key Cup II; Innovacon, Inc., San Diego,
CA) were used to assess cannabis, methamphetamines,
amphetamines, opioids, and cocaine use. The cutoff for
cannabis was 50ng/mL.
Intervention
The study consisted of a baseline interview, a 4-week pre-
treatment phase (weeks 1–4), a 12-week treatment phase
(weeks 5–12), and a 3-month follow-up phase (weeks
13–28). The variable magnitude of reinforcement proce-
dure was used to reinforce submission of urine samples
during the 4-week prerandomization phase and during
the treatment period.22 Participants were asked to attend
study visits three times a week onMondays, Wednesdays,
and Fridays. All participants participated in a 4-week pre-
randomization phase wherein they were eligible for three
prize draws each time they submitted a urine sample, re-
gardless of EtG results. After completing the prerandom-
ization phase, participants continued to receive treatment
as usual and were randomized into two groups, noncon-
tingent control (NC) or CM.NC participants were eligible
for incentives despite the results of their urine tests for al-
cohol. Participants in the CM condition received prize
draws only when their urine test was negative for alcohol
(EtG <150ng/mL). During the CM treatment phase, par-
ticipants also received a $5 or $10 gift card for attending
some or all of their scheduled outpatient addiction treat-
ment groups each week. NC participants received gift
cards equal to those earned by the CM group during
the previous week, regardless of whether they attended
addiction treatment group sessions.
Analyses
Descriptive analyses were conducted to describe the
number of individuals who submitted a cannabis-positive
urine test or reported cannabis use during the study. The
total number of cannabis-positive urine samples was
calculated across the entire sample (N = 121) and the
mean number of cannabis-positive urine tests was cal-
culated among cannabis users. Cannabis users were
defined as participants who submitted at least one
cannabis-positive urine sample throughout the study.
Differences were explored between cannabis users
and noncannabis users using chi-square tests for cate-
gorical variables, including sex, race, SMI diagnosis,
and urine drug (methamphetamines, amphetamines,
opioids, and cocaine) and alcohol use. Independent sam-
ples t-tests were used for continuous variables, such as
HRBS, BSI, and PANSS scores. Analysis of covariance
(ANCOVA) was used to determine whether the main ef-
fect of cannabis use was associated with the LDA from
alcohol in the randomized sample accounting for treat-
ment group membership (CM vs. control condition)
and pretreatment levels of EtG-assessed heavy drinking
(EtG >499ng/mL). We also conducted an ANCOVA
in the CM group only (n= 40) to determine whether
the main effect of cannabis use was associated with the
LDA, accounting for pretreatment levels of EtG-assessed
heavy drinking (EtG >499ng/mL). The criterion for sta-
tistical significance was set at alpha p< 0.05 and analyses
were conducted using IBM SPSS version 24.
Results
A total of 121 individuals met inclusion criteria and
provided informed consent. Participants had a mean
age of 45.4 (standard deviation [SD]= 10.1), 34.7%
(n = 42) were female, and 47% (n = 57) were nonwhite.
Thirty-five percent (n = 42) were diagnosed with major
depressive disorder, 38% (n = 46) with bipolar I or II
disorders, and 27% (n = 33) with schizophrenia spec-
trum disorders. Baseline demographics and clinical
characteristics are reported in Table 1.
A total of 2834 urine samples were submitted
throughout the study, with participants each submit-
ting a mean of 23.4 (SD= 16.2) urine samples during
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the study. Among the entire sample, 11.6% (n= 14)
reported having a medical marijuana card. However,
among those who were cannabis users (n= 57) during
the study, only 11 (19.3%) reported having a medical
marijuana card. Across the duration of the entire
study, 751 (26.5%) cannabis-positive urine samples
were submitted and 47% (n= 57) of participants sub-
mitted at least one cannabis-positive urine sample. Par-
ticipants who submitted at least one cannabis-positive
sample had a mean of 13.2 (SD= 13.5) cannabis-positive
samples. Although 57 participants submitted cannabis-
positive urine samples throughout the study, only 52
self-reported cannabis use in the 30 days before baseline.
Among the 52 participants who reported cannabis use in
the 30 days before baseline, participants reported a mean
11.7 days of cannabis use (SD= 10.9), with 11.5% (n= 6)
reporting cannabis use every day.
As described in Table 1, cannabis users weremore likely
to submit an alcohol-positive urine test at baseline (n=36,
63.2%), relative to noncannabis users (n=18, 28.1%),
v2 (1)=15, p<0.001. Cannabis users also had higher
mean HIV-risk scores on the sexual behavior subscale of
the HRBS (mean=3.5, SD=4.1), relative to noncannabis
users (mean=1.8, SD=2.5) t(89.9)=2.74, p=0.01. Can-
nabis users were more likely to submit a cocaine-positive
urine sample, v2 (1) = 6.5, p= 0.01 and be homeless,
v2 (1) = 4.9, p= 0.03, relative to noncannabis users.
Medical and legal problems were not significantly dif-
ferent across cannabis and noncannabis users.
In terms of the impact of cannabis use on treatment
outcomes in the randomized sample, pretreatment
heavy drinking, F(1,71)= 4.99, p< 0.05, but not canna-
bis use, F(1,71)= 0.45, p= 0.51, or treatment group,
F(1,71)= 2.43, p= 0.12, was significantly associated
with LDA from alcohol during CM, with heavy drinkers
having a shorter duration of abstinence relative to those
who did not engage in heavy drinking. This finding was
replicated within the CM group (n= 40). Pretreatment
Table 1. Baseline Demographic and Clinical Characteristics of the Evaluative Sample (N = 121)
Cannabis users Noncannabis users
n= 57 n = 64
n (%) Mean (SD) n (%) Mean (SD)
Demographic characteristics
Age 57 43.7 (10.9) 64 46.9 (9.2)
Male 39 (68.4) 40 (62.5)
Race
Caucasian 34 (59.6) 30 (46.9)
African American 11 (19.3) 23 (35.9)
Other 12 (21.1) 11 (17.2)
Homeless 22 (18.2a) 13 (10.7a)
Diagnosis
Major depressive disorder 18 (31.6) 24 (37.5)
Bipolar disorder 24 (42.1) 22 (34.4)
Schizophrenia-spectrum disorder 15 (26.3) 18 (25.1)
HRBS
Injection drug use 4 (7.1) 9 (14.3)
Sexual behavior 56 3.5a (4.1) 63 1.8a (2.5)
BSI
Total 54 90.2 (47.9) 62 78.5 (38.4)
PANSS
Positive symptoms 55 12.0 (4.2) 63 12.2 (4.4)
Negative symptoms 55 13.2 (5.1) 63 13.6 (5.4)
Emotional distress 55 17.6 (4.8) 63 17.9 (4.0)
Disorganization 55 20.1 (5.4) 63 20.4 (5.4)
Excitement 55 13.5 (14.0) 63 14.0 (3.6)
Other drug positives
Alcohol 36 (63.2a) 18 (28.1a)
Amphetamines 5 (8.8) 3 (4.7)
Methamphetamines 4 (7.0) 3 (4.7)
Cocaine 18 (31.6a) 8 (12.5a)
Opiates 2 (3.5) 2 (3.1)
aDifference is significant at p < 0.05.
BSI, Brief Symptom Inventory; HRBS, HIV Risk Taking Behavior Scale; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation.
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heavy drinking, F(1,37)= 7.45, p< 0.05, but not cannabis
use, F(1,37)= 0.09, p= 0.77, was significantly associated
with LDA from alcohol during CM.
Discussion
Approximately half the participants diagnosed with al-
cohol dependence and SMI participating in a clinical
trial of CM for AUDs submitted at least one cannabis-
positive urine sample during the study. More than one
out of every four urine samples submitted by cannabis
users was cannabis positive, suggesting regular ongoing
use. Cannabis use was not associated with duration of al-
cohol abstinence. This is consistent with findings that pre-
treatment cannabis use was not associated with alcohol
abstinence, regardless of whether it was for medical or
recreational purposes.7 This provides important informa-
tion to clinicians who must decide whether they should
treat comorbid cannabis use in their patients receiving
treatment for other substance use disorders, as it may
not affect the primary substance use treatment outcome.
Cannabis users engaged in higher levels of sexual
HIV-risk behaviors and were more likely to have an alco-
hol or cocaine-positive urine sample at baseline, indicat-
ing higher levels of very recent alcohol and drug use.
Cannabis users were also more likely to report homeless-
ness. The combination of AUDs and cannabis among
adults with SMI may be associated with increased se-
verity of substance use and risky behaviors that may,
in turn, be related to an increased likelihood of home-
lessness. These correlations may suggest that cannabis
users have a higher level of substance use severity or
that cannabis, alcohol, and cocaine use, and HIV-risk be-
haviors are all associated with an underlying factor, such
as high levels of impulsivity. Further research is needed
to better understand the nature of these associations.
There are several limitations to thesefindings. Foremost,
the researchwasnot an epidemiological investigation aswe
only recruited individuals with SMI enrolled in an alcohol
treatment study. Therefore, results might not generalize to
the entire population of adults with SMI, or to adults with
SMIwho also use illicit drugs.Wewere also not able to de-
scribe the exact amount, type, and route of administration
(e.g., smoked, eaten, and vaped) of daily cannabis use. In
addition, our subsample of individuals randomized to
CM was relatively small (n=40).
Despite the limitations of this secondary data analysis,
results highlight the high prevalence of cannabis use
among SMI outpatients receiving AUD treatment and
provide initial evidence that comorbid cannabis use
does not affect CM outcomes. Although the public health
debate regarding the health costs and benefits of cannabis
legalization has focused on youth, including youth at risk
for SMI, less is known about the impact of cannabis use
on other at-risk populations such as adults with SMI. As
an already vulnerable population, it is critical to under-
stand how cannabis use may exacerbate the many prob-
lems adults with SMI and AUDs already face. In
addition, it is unclear when adults with SMI and AUDs
are engaging in cannabis use and how this affects HIV-
risk behaviors and homelessness. For example, we do
not know whether these outcomes are largely driven by
the SMI, AUD, or cannabis use, or a combination of psy-
chopathology and substance use. Larger epidemiological
studies are needed to more definitively understand the
prevalence and correlates of cannabis use and its impact
on psychiatric and substance abuse treatment outcomes.
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